SUBSCRIBE
SUBSCRIBE

Ascidian Therapeutics

NEWS
Ribonucleic acid strands consisting of nucleotides important for protein bio-synthesis - 3d illustration
Drug Development
RNA Editing Hits the Clinic, Fueling New Hope for Rare and Common Diseases
With the modality now in early clinical trials, experts say more efficiency, broader editing capabilities and delivery breakthroughs are needed to propel RNA editing to the next stage.
February 24, 2025
 · 
6 min read
 · 
Heather McKenzie
Pictured: FDA sign at its office in Washington, DC/iStock, JHVEPhoto
Policy
FDA Clears Ascidian for First-Ever RNA Editing Trial in US
Ascidian Therapeutics, a member of BioSpace’s NextGen Class of 2024, on Monday announced it received IND clearance from the FDA and was granted Fast Track designation for ACDN-01.
January 30, 2024
 · 
2 min read
 · 
Tyler Patchen
Map of NextGen Class of 2024/BioSpace
Business
NextGen Class of 2024: Top Life Sciences Startups to Watch This Year
Rapport Therapeutics tops this year’s list with $250 million in Series A and B financing in just six months.
January 3, 2024
 · 
20 min read
 · 
BioSpace Editorial Staff
IN THE PRESS
Genetown
Ascidian Therapeutics to Present Preclinical Data for RNA Exon Editor, ACDN-01, Supporting an Open IND for Phase 1/2 Clinical Testing at ASGCT 2024 Annual Meeting
April 25, 2024
 · 
3 min read
Business
Ascidian Therapeutics Raises $40 Million in Series A Extension Financing from Apple Tree Partners and Appoints Michael Ehlers as Interim CEO
November 8, 2023
 · 
3 min read
AWARDS
  • NextGen Badge - Brighspot Rework_NextGen - Class of 2024.jpg
JOBS